NCT06326502View on ClinicalTrials.gov

A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 7, 2024

Primary Completion Date

March 7, 2027

Study Completion Date

June 7, 2027

Conditions
Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaLiver Cancer
Interventions
DRUG

ETN101

Oral administration

Trial Locations (2)

03080

RECRUITING

Seoul National University Hospital, Seoul

03722

RECRUITING

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Etnova Therapeutics Corp.

INDUSTRY